Longer trastuzumab duration ( hera : 2 years vs. 1 year ) showed no improvement in dfs or os and a higher rate of cardiac events .
In the neoadjuvant setting ( neoaltto , GeparQuinto , Neosphere ) , trastuzumab alone or in combination with another anti-her2 agent ( lapatinib , pertuzumab ) was compared with either lapatinib or pertuzumab alone and showed superior or equivalent rates of pathologic complete response .
In the adjuvant setting , lapatinib alone or in combination with trastuzumab , compared with trastuzumab alone ( altto ) or with placebo ( teach ) , was not superior in dfs .
BACKGROUND This systematic review addresses the question " What is the optimal targeted therapy for female patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer ? "
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
PURPOSE To assess cardiac safety and potential cardiac risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial . PATIENTS AND METHODS Patients with HER2-positive operable breast cancer were r and omly assigned to doxorubicin plus cyclophosphamide ( AC ) followed by either weekly paclitaxel ( arm A ) ; paclitaxel then trastuzumab ( arm B ) ; or paclitaxel plus trastuzumab then trastuzumab alone ( arm C ) . Left ventricular ejection fraction ( LVEF ) was evaluated at registration and 3 , 6 , 9 , and 18 to 21 months . RESULTS Of 2,992 patients completing AC , 5.0 % had LVEF decreases disallowing trastuzumab ( decrease below normal : 2.4 % , decrease > 15 % : 2.6 % ) . There were 1,944 patients with satisfactory or no LVEF evaluation who proceeded to post-AC therapy . Cardiac events ( congestive heart failure [ CHF ] or cardiac death [ CD ] ) : arm A , n = 3 ( 2 CHF , 1 CD ) ; arm B , n = 19 ( 18 CHF , 1 CD ) ; arm C , n = 19 ( all CHF ) ; 3-year cumulative incidence : 0.3 % , 2.8 % , and 3.3 % , respectively . Cardiac function improved in most CHF cases following trastuzumab discontinuation and cardiac medication . Factors associated with increased risk of a cardiac event in arms B and C : older age ( P < .003 ) , prior/current antihypertensive agents ( P = .005 ) , and lower registration LVEF ( P = .033 ) . Incidence of asymptomatic LVEF decreases requiring holding trastuzumab was 8 % to 10 % ; LVEF recovered and trastuzumab was restarted in approximately 50 % . CONCLUSION The cumulative incidence of post-AC cardiac events at 3 years was higher in the trastuzumab-containing arms versus the control arm , but by less than 4 % . Older age , lower registration LVEF , and antihypertensive medications are associated with increased risk of cardiac dysfunction in patients receiving trastuzumab following AC
Longer trastuzumab duration ( hera : 2 years vs. 1 year ) showed no improvement in dfs or os and a higher rate of cardiac events .
In the neoadjuvant setting ( neoaltto , GeparQuinto , Neosphere ) , trastuzumab alone or in combination with another anti-her2 agent ( lapatinib , pertuzumab ) was compared with either lapatinib or pertuzumab alone and showed superior or equivalent rates of pathologic complete response .
In the adjuvant setting , lapatinib alone or in combination with trastuzumab , compared with trastuzumab alone ( altto ) or with placebo ( teach ) , was not superior in dfs .
BACKGROUND This systematic review addresses the question " What is the optimal targeted therapy for female patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer ? "